{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:22:06Z","timestamp":1761513726765},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Shire Human Genetic Therapies"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.expneurol.2015.11.013","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T01:46:11Z","timestamp":1448502371000},"page":"11-21","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder"],"prefix":"10.1016","volume":"278","author":[{"given":"Barbara","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan L.","family":"Setford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Hassiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Trim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Duplock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin N.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marten F.","family":"Snel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Hopwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim M.","family":"Hemsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2015.11.013_bb0005","series-title":"Continual low-Dose Infusion of Sulfamidase is Superior in Ameliorating Neuropathology in the MPS IIIA Mouse Brain to Intermittent High-dose Delivery","author":"Beard","year":"2015"},{"key":"10.1016\/j.expneurol.2015.11.013_bb0010","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/pme.12481","article-title":"Treatment of medically refractory cancer pain with a combination of intrathecal neuromodulation and neurosurgical ablation: case series and literature review","volume":"15","author":"Bentley","year":"2014","journal-title":"Pain Med."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0015","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1073\/pnas.082011999","article-title":"Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors","volume":"99","author":"Brooks","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0020","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.expneurol.2010.07.023","article-title":"Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease","volume":"225","author":"Cabrera-Salazar","year":"2010","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.expneurol.2015.11.013_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030341","article-title":"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2015.11.013_bb0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/mt.2008.9","article-title":"Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Chang","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.05.079","article-title":"Characterisation of a C57BL\/6 congenic mouse strain of mucopolysaccharidosis type IIIA","volume":"1104","author":"Crawley","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nbd.2011.04.014","article-title":"Enzyme replacement reduces neuropathology in MPS IIIA dogs","volume":"43","author":"Crawley","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.conb.2013.01.013","article-title":"Towards new approaches to disorders of fear and anxiety","volume":"23","author":"Dias","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2010.06.020","article-title":"Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I","volume":"101","author":"Dickson","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.expneurol.2008.10.021","article-title":"Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann\u2013Pick A disease","volume":"215","author":"Dodge","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0060","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/hmg\/ddm223","article-title":"Functional correction of CNS lesions in a MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes","volume":"16","author":"Fraldi","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0065","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of Mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood\u2013brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1203\/01.PDR.0000129661.40499.12","article-title":"Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice","volume":"56","author":"Gliddon","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0075","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/ejn.12557","article-title":"Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease","volume":"39","author":"Hassiotis","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbr.2004.08.019","article-title":"Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA)","volume":"158","author":"Hemsley","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0085","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1460-9568.2009.06666.x","article-title":"Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease","volume":"29","author":"Hemsley","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2009.07.013","article-title":"Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs\u2014a proof of principle study","volume":"98","author":"Hemsley","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0095","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1601-183X.2008.00413.x","article-title":"Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice","volume":"7","author":"Hemsley","year":"2008","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2006.10.005","article-title":"Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice","volume":"90","author":"Hemsley","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0105","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1194\/jlr.D800038-JLR200","article-title":"Targeted analysis of ganglioside and sulphatide molecular species by LC\/ESI-MS\/MS with theoretically expanded multiple reaction monitoring","volume":"49","author":"Ikeda","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","article-title":"Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I","volume":"83","author":"Kakkis","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0115","doi-asserted-by":"crossref","first-page":"14870","DOI":"10.1073\/pnas.1416660111","article-title":"Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB","volume":"111","author":"Kan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0120","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF01799255","article-title":"A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type A (MPS IIIA)","volume":"19","author":"Karpova","year":"1996","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0125","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jnr.23423","article-title":"Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)","volume":"92","author":"Katz","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.expneurol.2015.11.013_bb9000","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.13533","article-title":"Low dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal storage disorder, MPS IIIA","author":"King","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10545-014-9790-8","article-title":"Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain","volume":"38","author":"King","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.expneurol.2011.04.019","article-title":"Treatment of canine fucosidosis by intracisternal enzyme infusion","volume":"230","author":"Kondagari","year":"2011","journal-title":"Exp. Neurol."},{"issue":"10","key":"10.1016\/j.expneurol.2015.11.013_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025717","article-title":"Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test","volume":"6","author":"Langford-Smith","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.expneurol.2015.11.013_bb0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbr.2008.03.024","article-title":"Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice","volume":"191","author":"Lau","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0150","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.expneurol.2010.07.024","article-title":"Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice","volume":"225","author":"Lau","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0155","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1096\/fj.06-6169com","article-title":"Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy","volume":"21","author":"Lee","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0160","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.mt.6300016","article-title":"Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS","volume":"15","author":"Liu","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0165","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1523\/JNEUROSCI.2936-05.2005","article-title":"Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors","volume":"25","author":"Liu","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0170","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clineuro.2014.05.024","article-title":"Intrathecal baclofen therapy for the symptomatic treatment of hereditary spastic paraplegia","volume":"123","author":"Margetis","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.expneurol.2014.09.008","article-title":"Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods","volume":"263","author":"Marshall","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clineuro.2014.05.012","article-title":"Neurosurgical treatment for dystonia: long-term outcome in a case series of 80 patients","volume":"123","author":"Mart\u00ednez","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0185","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/hmg\/dds086","article-title":"Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age","volume":"21","author":"Matthes","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0190","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.expneurol.2015.11.013_bb0195","series-title":"The Mouse Brain in Stereotaxic Co-ordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.expneurol.2015.11.013_bb0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.expneurol.2011.04.004","article-title":"Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA","volume":"230","author":"Rozaklis","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0205","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/hum.2012.029","article-title":"Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPS IIIA mice through systemic AAV9 gene transfer","volume":"23","author":"Ruzo","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0210","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.gt.3302883","article-title":"Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer","volume":"14","author":"Sevin","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0215","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ajmg.a.35869","article-title":"Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice","volume":"161A","author":"Sohn","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.expneurol.2015.11.013_bb0220","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201202083","article-title":"A highly secreted sulphamidase engineered to cross the blood\u2013brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA","volume":"5","author":"Sorrentino","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0225","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/hmg\/ddr175","article-title":"Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy","volume":"20","author":"Stroobants","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0230","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/rcm.6861","article-title":"A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA","volume":"28","author":"Trim","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0235","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ana.22262","article-title":"Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis","volume":"69","author":"Tsuji","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0240","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.22092","article-title":"Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations","volume":"68","author":"Valstar","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0245","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo syndrome: a mini-review","volume":"31","author":"Valstar","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0250","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ymgme.2011.03.011","article-title":"Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations","volume":"103","author":"Vite","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2015.11.013_bb0255","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.20392","article-title":"Effective gene therapy for an inherited CNS disease in a large animal model","volume":"57","author":"Vite McGowan","year":"2005","journal-title":"Ann. Neurol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488615301266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488615301266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T14:53:42Z","timestamp":1617461622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488615301266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":52,"alternative-id":["S0014488615301266"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2015.11.013","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose, continual enzyme delivery ameliorates some aspects of established brain disease in a mouse model of a childhood-onset neurodegenerative disorder","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2015.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}